This investigation served to further demonstrate that the combination therapies involving FAK or TEAD inhibitors and osimertinib not only induced more profound and long-lasting responses but also impaired tumor re-growth following the discontinuation of drug treatment at the minimal residual disease (MRD) state. This evidence concerns the gene PTK2 and neoplasm.